Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females 12 years or older~* History of persistent bronchial asthma for at least 6 months~* Documented use of an inhaled steroid or a combination of an inhaled steroid/long-acting beta 2 agonist for at least 1 month before screening~* At screening, FEV1 of 60 to 90% predicted or 70 to 95% predicted for either ICS or ICS/LABA use respectively.Reversibility of FEV1 by at least 12% and 200 ml post-bronchodilator~* Be able to use oral inhalers~* Non-smokers~Exclusion Criteria:~* History of life-threatening asthma~* Other pulmonary diseases; URI within 4 weeks before screening~* Use of systemic steroids within 1 month before screening or more than 3 times in previous 6 months~* Beta-adrenergic blocking agent use~* More than 2 in-patient hospitalizations or ER visits due to asthma exacerbations in the prior year before screening~* Pregnant or breast-feeding females~* Females of child-bearing potential not using adequate means of birth control~* Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major systemic disease~* Abnormal clinical laboratory parameters that would limit participation in the study or interfere with interpretation of study results~* History of drug or alcohol abuse~* Treatment with any investigational product within 30 days prior to study entry

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).